Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • PERIOD ANALYSIS  (24)
  • UNITED-STATES  (16)
Collection
Keywords
  • 11
    Keywords: SURVIVAL ; Germany ; COHORT ; EPIDEMIOLOGY ; PATIENT ; PERFORMANCE ; PATTERNS ; DATABASE ; LONG-TERM SURVIVAL ; UNITED-STATES ; TRENDS ; EUROPE ; MULTIPLE-MYELOMA ; multiple myeloma ; cancer registries ; PERIOD ANALYSIS ; thalidomide ; EMPIRICAL-EVALUATION ; cancer survival ; UP-TO-DATE ; OLDER
    Abstract: New therapeutic options have led to substantial increases in survival expectations of younger patients with multiple myeloma in recent years. In the past, the impact of these innovations on long-term survival has been disclosed only with substantial delay. We aimed to derive up-to-date estimates of long-term survival expectations of concurrently diagnosed multiple myeloma patients. Using data from the 1973-2005 database of the Surveillance, Epidemiology, and End Results (SEER) Program, we employed a novel model-based projection method to project 5-and 10-year relative survival expectations of multiple myeloma patients in the United States diagnosed in 2006-2010. Preliminary empirical evaluation of the method using historical data indicated good performance. Projected 5-year relative survival for patients diagnosed in 2006-2010 below 45 years of age is 68.0%, which exceeds the most up-to-date estimates obtained from traditional cohort and period analysis by 15.5 and 7.0 percent units respectively. Ten-year relative survival projection for patients in this age group is 55.3%, exceeding the most up-to-date estimates from traditional cohort and period analysis by 19.7 and 7.4 percent units respectively. By contrast, survival projections remain much lower and hardly exceed estimates from traditional survival analysis for older patients. Patients diagnosed with multiple myeloma in 2006-2010, especially those diagnosed at younger ages, are expected to have much higher long-term survival perspectives than suggested by previously available survival statistics
    Type of Publication: Journal article published
    PubMed ID: 19144659
    Signatur Availability
    BibTip Others were also interested in ...
  • 12
    Keywords: CANCER ; SURVIVAL ; evaluation ; Germany ; THERAPY ; COHORT ; DISEASE ; EPIDEMIOLOGY ; LONG-TERM ; POPULATION ; PATIENT ; prognosis ; PERFORMANCE ; LYMPHOMA ; AGE ; statistics ; chemotherapy ; DATABASE ; LONG-TERM SURVIVAL ; EUROPE ; Hodgkin's lymphoma ; REGISTRY ; THERAPIES ; cancer registries ; PERIOD ANALYSIS ; RELATIVE SURVIVAL ; LEVEL ; USA ; population-based ; EMPIRICAL-EVALUATION ; PROGRESS ; cancer survival ; ERROR ; SPREAD ; ABVD
    Abstract: Available long-term survival figures for patients with Hodgkin's lymphoma (HL) from population-based cancer registries mostly refer to patients diagnosed in the 1980s and 1990s, and do not reflect recent progress in and spread of effective therapy at the population level. Using data from the Surveillance, Epidemiology, and End Results program, we employed a novel model-based projection method to estimate 5- and 10-year relative survival expectations of HL patients in the U. S. diagnosed in 2006-2010. Preliminary empirical evaluation of the method using historical data indicates excellent performance. Projections of 10-year relative survival percentages and their standard errors by age groups are as follows: 15-24 y: 94.7 (1.1), 25-34 years, 89.4 (1.5); 35-44 years, 90.1 (1.6); 45-54 years, 83.6 (2.7); 55-64 years, 70.5 (4.7); 65-74 years, 48.5 (5.9); and 75+ years, 24.0 (5.7). These estimates are 2.5-11.1 percentage points higher than those obtained by standard cohort analysis from the same database ( pertaining to patients diagnosed in 1991-1995). Patients diagnosed with HL in 2006-2010 have higher long-term survival expectations than suggested by conventional survival statistics from population-based cancer registries. The 10-year survival expectations are now close to or exceed 90% in all age groups up to age 45, and exceed 80% and 70% in the 45-54 and 55-64 age groups, respectively. The Oncologist 2009; 14: 806-813
    Type of Publication: Journal article published
    PubMed ID: 19648314
    Signatur Availability
    BibTip Others were also interested in ...
  • 13
    Keywords: CANCER ; SURVIVAL ; Germany ; DISEASE ; EPIDEMIOLOGY ; RISK ; PATIENT ; prognosis ; LYMPHOMA ; chemotherapy ; DATABASE ; UNITED-STATES ; TRENDS ; B-CELL LYMPHOMA ; PERIOD ANALYSIS ; development ; non-Hodgkin lymphoma ; EMPIRICAL-EVALUATION ; UP-TO-DATE ; ACTIVE ANTIRETROVIRAL THERAPY ; PLUS RITUXIMAB ; prior malignancy
    Abstract: An increased risk of non-Hodgkin lymphoma (NHL) has been observed in the survivors of several malignancies. Survival for patients with primary NHL has improved in the 1990s and early 21st century, but population-based survival data for patients diagnosed with NHL after a prior malignancy are lacking. We estimated trends in age-specific 5- and 10-year relative survival of NHL patients with prior malignancy in the United States from 1990-1994 to 2000-2004 using the Surveillance, Epidemiology and End Results Program database. Period analysis of survival was employed to disclose recent developments with minimum delay. Five- and 10-year relative survival has strongly improved for NHL patients with prior malignancy between 1990-1994 and 2000-2004, from 38.0 to 54.1% and 24.4 to 41.0%, respectively. Despite a strong increase in relative survival over time, patients with prior malignancies continued to have a worse prognosis compared with those with no prior malignancy
    Type of Publication: Journal article published
    PubMed ID: 19197735
    Signatur Availability
    BibTip Others were also interested in ...
  • 14
    Keywords: CANCER ; SURVIVAL ; Germany ; DIAGNOSIS ; DISEASE ; EPIDEMIOLOGY ; PATIENT ; EXPERIENCE ; WOMEN ; CLINICAL-TRIALS ; MEN ; DATABASE ; UNITED-STATES ; ADULTS ; PERIOD ANALYSIS ; EMPIRICAL-EVALUATION ; UP-TO-DATE ; OLDER
    Abstract: Acute lymphoblastic leukemia ( ALL) is an uncommon but highly fatal disease in adults. We used period analysis to data from the Surveillance, Epidemiology, and End Results ( SEER) database to disclose changes in outcomes for patients diagnosed with ALL in the United States in the 2 decades between 1980-1984 and 2000-2004. Major improvement in survival was observed for patients less than 60 years of age. Improvement in survival was greater for women than for men, but was significant for both genders. The greatest improvement was seen in patients aged 15 to 19, in whom 5-year relative survival improved from 41.0% to 61.1%, and 10-year survival improved from 33.0% to 60.4%. Lesser but significant improvements were seen for age groups 20-29, 30-44, and 45-59. Survival for patients aged 60 and over remained essentially unchanged at levels around or below 10%, respectively. Survival has improved for patients with ALL over the time period studied, but treatment of older patients remains a difficult issue. ( Blood. 2009; 113: 1408-1411)
    Type of Publication: Journal article published
    PubMed ID: 18974371
    Signatur Availability
    BibTip Others were also interested in ...
  • 15
    Keywords: ACID ; UNITED-STATES ; TRENDS ; HEMATOLOGIC MALIGNANCIES ; ACUTE PROMYELOCYTIC LEUKEMIA ; ADULTS ; PERIOD ANALYSIS ; ACUTE MYELOID-LEUKEMIA ; cancer survival
    Abstract: BACKGROUND: Treatment of acute myeloblastic leukemia (AML) has evolved over the past several decades. Therefore, currently available estimates of long-term survival, which are based on survival for patients treated with potentially now obsolete protocols, may not pertain to patients currently diagnosed. METHODS: Using data from the 1973-2005 database of the Surveillance, Epidemiology, and End Results Program, we empirically validated a novel model-based method to project 5- and 10-year relative survival of AML patients and we applied the method to project relative survival of AML patients in the United States diagnosed during 2006-2010. RESULTS: Empirical evaluation indicated that the modeling approach provides more accurate estimates of currently diagnosed patients than standard methods of survival analysis, such as cohort analysis or period analysis, in the majority of cases. Projected figures for 2006-2010 show 5- and 10-year relative survival estimates of 21.4% and 18.7% for all ages combined, 62.2% and 57.4% for ages 25-34, and 60.6% and 58.1% for ages 35-44. These estimates are substantially higher than the most up-to-date estimates obtained by standard survival analysis. CONCLUSION: Patients diagnosed with AML during 2006-2010 at younger ages have much higher long-term survival expectations than indicated by previously available survival statistics.
    Type of Publication: Journal article published
    PubMed ID: 19633049
    Signatur Availability
    BibTip Others were also interested in ...
  • 16
    Keywords: BREAST-CANCER ; LYMPHOMA ; LONG-TERM SURVIVAL ; SURVEILLANCE ; MULTIPLE-MYELOMA ; PERIOD ANALYSIS ; IMPROVEMENT ; UP-TO-DATE ; DISPARITIES ; RACE
    Abstract: Background Patients of minority race/ethnicity have lower survival after diagnosis with most types of cancer. Little data are available concerning changes in disparity over time. Here, we examine changes in survival by race/ethnicity of patients with common cancers in two recent time periods. Patients and methods We used modeled period analysis to determine relative survival (RS) for non-Hispanic white (nHw), African-American (AA), and Hispanic patients in the Surveillance, Epidemiology, and End Results database diagnosed with common solid and hematological malignancies. Results Five-year RS improved overall and for nHw for each tumor examined, ranging from + 2% points (pancreatic cancer) to + 16.4% points [non-Hodgkin's lymphoma, (NHL)]. Greater improvement was observed for AA and Hispanics than nHw in breast and prostate cancer and NHL. Less improvement was observed for AA and Hispanics than for nHw for lung and pancreatic cancer. No statistically significant improvement was observed for AA and Hispanics with myeloma or acute leukemia. Survival disparities ranging from 0.5% points (myeloma) to 13.1% points (breast) between nHw and AA remained. Conclusions Progress has been made in decreasing disparities in survival between nHw and minorities in breast cancer, prostate cancer, and NHL. Little progress has been made in reducing disparities for the other studied cancers.
    Type of Publication: Journal article published
    PubMed ID: 22396445
    Signatur Availability
    BibTip Others were also interested in ...
  • 17
    Keywords: CANCER ; ASSOCIATION ; LONG-TERM SURVIVAL ; UNITED-STATES ; B-CELL LYMPHOMA ; OLDER PATIENTS ; ACUTE MYELOID-LEUKEMIA ; SOCIOECONOMIC-STATUS ; PLUS RITUXIMAB ; EARLY 21ST-CENTURY
    Abstract: Background. New treatment options and supportive care measures have greatly improved survival of patients with non-Hodgkin lymphoma (NHL) but may not be affordable for those with no insurance or inadequate insurance. Methods. Using data from the Surveillance, Epidemiology, and End Results database, we estimated overall and cause-specific survival according to insurance status within 3 years after diagnosis of patients diagnosed with NHL in the U.S. in the period 2007-2011. Because NHL is a heterogeneous condition, we also examined survival in diffuse large B-cell lymphoma (DLBCL). Results. Survival was higher for patients with non-Medicaid insurance compared with either uninsured patients or patients with Medicaid. For patients with any NHL, the 3-year survival estimates were 68.0% for uninsured patients, 60.7% for patients with Medicaid, and 84.9% for patients with non-Medicaid insurance. Hazard ratios (HRs) for uninsured and Medicaid-only patients compared with insured patients were 1.92 (95% confidence interval [CI]: 1.76-2.10) and 2.51 (95% CI: 2.36-2.68), respectively. Results were similar for patients with DLBCL, with survival estimates of 68.5% for uninsured patients (HR: 1.78; 95% CI: 1.57-2.02), 58%, for patients with Medicaid (HR: 2.42; 95% CI: 2.22-2.64), and 83.3% for patients with non-Medicaid insurance. Cause-specific analysis showed survival estimates of 80.3% for uninsured patients (HR: 1.83; 95% CI: 1.62-2.05), 77.7% for patients with Medicaid (HR: 2.23; 95% CI: 2.05-2.42), and 90.5% for patients with non-Medicaid insurance. Conclusion. Lack of insurance and Medicaid only were associated with significantly lower survival for patients with NHL. Further evaluation of the reasons for this disparity and implementation of comprehensive coverage for medical care are urgently needed.
    Type of Publication: Journal article published
    PubMed ID: 25876991
    Signatur Availability
    BibTip Others were also interested in ...
  • 18
    Keywords: LONG-TERM SURVIVAL ; PERIOD ANALYSIS ; MELPHALAN ; prednisone ; IMPROVEMENT ; cancer survival ; UP-TO-DATE ; BORTEZOMIB ; INITIAL TREATMENT ; LENALIDOMIDE PLUS DEXAMETHASONE
    Abstract: Multiple myeloma is a chronic, incurable but highly treatable neoplasm. Recent population-based studies have shown improvements in survival for patients diagnosed in the early 21st century. Here, we examine trends in survival for patients diagnosed with multiple myeloma in Germany and the United States (US) between 2002 and 2010. Data were extracted from 11 population-based cancer registries in Germany and from the Surveillance, Epidemiology and End Results database in the US. Myeloma patients aged 15-74 years with diagnosis and follow-up between 1997 and 2010 from Germany and the US were included. Period analysis was employed to assess trends in 5-year relative survival in Germany and the US between 2002-04 and 2008-10. Age-adjusted 5-year relative survival increased from 47.3% to 53.8% in Germany and from 39.8% to 53.2% in the US between 2002-04 and 2008-10. There was a strong age gradient with lower survival among older patients, which persisted over time and was more pronounced in Germany than the US. Five-year relative survival estimates for patients diagnosed with multiple myeloma below 75 years of age steadily increased throughout the first decade of the 21st century and reached levels above 50% in both Germany and the US, probably reflecting the increased use of newer agents in myeloma treatment.
    Type of Publication: Journal article published
    PubMed ID: 26123295
    Signatur Availability
    BibTip Others were also interested in ...
  • 19
    Keywords: CANCER ; SURVIVAL ; BLOOD ; Germany ; THERAPY ; DIAGNOSIS ; EPIDEMIOLOGY ; LONG-TERM ; PATIENT ; NO ; AGE ; DATABASE ; SURVEILLANCE ; UNITED-STATES ; STEM-CELL TRANSPLANTATION ; TRENDS ; MULTIPLE-MYELOMA ; STATES ; AUTOLOGOUS TRANSPLANTATION ; RE ; THERAPIES ; ELDERLY-PATIENTS ; INCREASE ; PERIOD ANALYSIS ; thalidomide ; analysis ; technique ; dexamethasone ; USA ; EMPIRICAL-EVALUATION ; INCREASES ; UP-TO-DATE ; UNTREATED PATIENTS
    Abstract: In the past, most patients with multiple myeloma (MM) died within 5 to 10 years after diagnosis. Within the past decade, several new therapeutic interventions have been introduced, including autologous stem-cell transplantation, thalidomide, lenalidomide, and bortezomib. We estimated trends in age-specific 5- and 10-year relative survival of patients with MM in the United States from 1990-1992 to 2002-2004 from the 1973-2004 database of the Surveillance, Epidemiology, and End Results (SEER) Program. Techniques of period analysis were used to show most recent developments. Overall, 5-year relative survival increased from 28.8% to 34.7% (P 〈.001), and 10-year relative survival increased from 11.1% to 17.4% (P 〈.001) between 1990-1992 and 2002-2004. Much stronger increases were seen in the age group younger than 50 years, leading to 5- and 10-year relative survival of 56.7% and 41.3% in 20022004, and in the age group 50 to 59 years, leading to 5- and 10-year relative survival of 48.2% and 28.6% in 200-2004. By contrast, only moderate improvement was seen in the age group 60 to 69 years, and essentially no improvement was achieved among older patients. Our period analysis discloses a major increase in long-term survival of younger patients with MM in recent years, which most likely reflects the effect of recent advances in therapy and their dissemination in clinical practice
    Type of Publication: Journal article published
    PubMed ID: 17901246
    Signatur Availability
    BibTip Others were also interested in ...
  • 20
    Keywords: SURVIVAL ; BLOOD ; COMBINATION ; Germany ; DISEASE ; EPIDEMIOLOGY ; LONG-TERM ; POPULATION ; PATIENT ; prognosis ; LYMPHOMA ; AGE ; chemotherapy ; DATABASE ; SURVEILLANCE ; UNITED-STATES ; TRENDS ; STATES ; RE ; ELDERLY-PATIENTS ; INCREASE ; PERIOD ANALYSIS ; LEVEL ; analysis ; USA ; EMPIRICAL-EVALUATION ; INCREASES ; TO-DATE ; CHILDHOOD-CANCER SURVIVOR ; COLLABORATIVE BRITISH COHORT ; COPP-ABVD ; STUDY-GROUP GHSG
    Abstract: Since the breakthroughs in combination chemotherapy of patients with Hodgkin disease (HD) starting in the 1960s, prognosis of patients has been rising steadily. Trends in long-term survival of patients with HD on the population level should therefore be monitored in an as timely as possible manner. We assessed trends in age specific 5- and 10-year relative survival of patients with HD in the United States from 1980-1984 to 2000-2004 from the 1973-2004 database of the Surveillance, Epidemiology, and End Results (SEER) Program. Period analysis was used to disclose recent developments with minimum delay. Overall, 5-year relative survival steadily increased from 73.5% to 85.2% (+11.7 percentage units), and 10-year relative survival increased from 62.1% to 80.1% (+18.0 percentage units) between 1980-1984 and 2000-2004, according to period analysis. The increase was particularly pronounced for patients aged 45 to 59 years and 60 years and older (increases in 10-year relative survival by 24.8 and 23.3 percentage points, respectively). Nevertheless, a strong age gradient persisted, with 10-year relative survival of 92.7%, 88.7%, 84.9%, 76.2%, and 44.9% in patients aged 15 to 24 years, 25 to 34 years, 35 to 44 years, 45 to 54 years, and 60 years and older, respectively, in 2000-2004. Our period analysis discloses ongoing, major improvement in long-term survival of patients with HD in recent years, particularly among older patients
    Type of Publication: Journal article published
    PubMed ID: 18096762
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...